As predicted in last month’s issue of LIR, molecular diagnostics company Tm Bioscience (Toronto, Canada) has been acquired. The buyer is not a large national laboratory but IVD company Luminex (Austin, TX), best known for its xMAP testing platform. Under the terms of the agreement, valued at $37.9 million, each Tm Bioscience share will be exchanged for 0.06 shares of Luminex common stock. This represents a 41.5% premium for Tm shares based on the stock’s closing price on the day of the acquisition. The transaction is expected to close in the first quarter of this year.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

January 2007 - Table of Contents

LIR January 2007 (full PDF issue)

Competitive Bidding Demo in Holding Pattern Awaiting OMB’s OK

Sonic to Acquire American Esoteric Laboratories for $180M

LabCorp Buys Kansas Lab

What Does ’07 Hold for LabCorp? LIR’s Interview With New CEO Dave King

Lab Industry Awaits First Domino of Competitive Bidding Project to Tip

Spotlight on Pap Testing: Monolayer Testing to Take 100% of Market in ’07?

BD Closes on $350m TriPath Acquisition

Luminex to Buy Tm Bioscience for $37.9M

Aetna Contracts With Genomic Health for Oncotype DX

Lab Stocks Rise 4%; Clarient and Genomic Health Soar 27%

Integrating MDx Conference